Love is on the Air: The March to Cure Sickle Cell Disease

Global Blood Therapeutics’ CEO Ted Love on his company’s mission to transform the lives of patients with the “first molecular disease”.

Love staunchly defended Oxbryta’s list price of $125,000/year, which has sparked some criticism, as GBT continues its research on additional therapies . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articlePleasurable Dopamine Impulses Can Be Controlled at Will, Mouse Studies Show
Next articlePerkinElmer to Acquire Antibody, Reagent Maker BioLegend for $5.25B